Can You Keep Your Bladder After Bladder Cancer Strikes?
Title: Can You Keep Your Bladder After Bladder Cancer Strikes?Category: Health NewsCreated: 6/7/2021 12:00:00 AMLast Editorial Review: 6/7/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 7, 2021 Category: Cancer & Oncology Source Type: news

Study shows novel test can detect new and recurrent bladder cancer
Detection of bladder cancer is often difficult and expensive, but this non-invasive urine screening test could make a significant positive impact. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 4, 2021 Category: Universities & Medical Training Source Type: news

Immunotherapy after bladder cancer surgery may reduce recurrence, study shows
(Memorial Sloan Kettering Cancer Center) ew research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo ® ) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published in theNew England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news

Immunotherapy after surgery reduces deadly relapse risk in advanced bladder cancer
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A phase 3 clinical trial co-led by Mount Sinai researchers is the first to show that immunotherapy after surgery to remove bladder cancer can reduce the risk of relapse for patients who are at high risk of their cancer returning in a deadly metastatic form, according to results published in The New England Journal of Medicine. The immunotherapy nivolumab was used as an adjuvant therapy, which is given after surgery in the hopes of maximizing its effectiveness. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2021 Category: Cancer & Oncology Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Finding new cost-effective treatment options for BCG-unresponsive bladder cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Oncotarget: Progression in high-risk non-muscle invasive bladder cancer
(Impact Journals LLC) This Oncotarget study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2021 Category: Cancer & Oncology Source Type: news

Cancer symptoms: Toilet troubles may be indicative of a growing tumour – signs
CANCER can influence how you use the toilet. A growing tumour - depending on where it is - can cause difficulties when it comes to emptying the bowels and bladder. Here are the warning signs to take note of. (Source: Daily Express - Health)
Source: Daily Express - Health - May 30, 2021 Category: Consumer Health News Source Type: news

Oncotarget: Urine protein biomarkers of bladder cancer
(Impact Journals LLC) These Oncotarget findings suggest that urine IL-1α, IL-1ra and IL-8 are useful indicators of bladder cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news

Mayo Clinic Q & amp;A podcast: Bladder cancer patients require ongoing surveillance
Bladder cancer is a common type of cancer that begins in the cells of the bladder, a hollow muscular organ in the lower abdomen that stores urine. Bladder cancer signs and symptoms can include blood in the urine, frequent or painful urination, and back pain. "The vast majority of bladder cancer patients are diagnosed with cancer that's not [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 17, 2021 Category: Databases & Libraries Source Type: news

Consumer Health: Bladder cancer awareness
May is Bladder Cancer Awareness Month, which makes this a good time to learn more about bladder cancer. Bladder cancer is one of the most common cancers. Nearly 84,000 new cases will be diagnosed in the U.S. in 2021, according to the American Cancer Society. Bladder cancer occurs in men more frequently than in women, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 13, 2021 Category: Databases & Libraries Source Type: news

How Long Will You Live if You Have Bladder Cancer?
Title: How Long Will You Live if You Have Bladder Cancer?Category: Diseases and ConditionsCreated: 5/6/2021 12:00:00 AMLast Editorial Review: 5/6/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 6, 2021 Category: Cancer & Oncology Source Type: news

What Are the Different Stages of Bladder Cancer?
Title: What Are the Different Stages of Bladder Cancer?Category: Diseases and ConditionsCreated: 4/30/2021 12:00:00 AMLast Editorial Review: 4/30/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 30, 2021 Category: Cancer & Oncology Source Type: news

To Stay: Two More Cancer Indications With'Dangling Approvals'To Stay: Two More Cancer Indications With'Dangling Approvals '
On the second day of a historic meeting, FDA advisers voted to keep the accelerated approvals for two immunotherapies for use in bladder cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for previously untreated metastatic bladder cancer
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) for the treatment of adults with locally advanced or metastatic urothel ial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumours express high levels of PD-L1 (PD-L1–stained tumour-infiltrating immune cells covering ≥5 percent of the tumour area) as determined by an FDA-approved test or are not eligible for any platinum...
Source: Roche Investor Update - April 28, 2021 Category: Pharmaceuticals Source Type: news